Treatment Patterns of Neratinib in HER2+ EBC in China

Inclusion Criteria

• •Signed written informed consent approved by the reviewing Ethics Committee (EC).
• •Adult patients (≥18 years of age, no upper limit).
• •Eligible to receive neratinib for extended adjuvant treatment as per prescribing information in China, diagnosed with HER2 overexpressing/amplified early-stage breast cancer regardless of hormone receptor (HR) status and clinical/radiological assessed to be negative for recurrences or metastatic disease.